Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Maria V. Deligiorgi & Dimitrios T. Trafalis. (2021) The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. Expert Opinion on Drug Safety 20:2, pages 191-213.
Read now
Read now
Kun-Hung Lai, Chih-Yung Chiang, Rong-Sen Yang, Kai-Chiang Yang & Chang-Chin Wu. (2019) Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease. Acta Clinica Belgica 74:5, pages 370-374.
Read now
Read now
Daniel C Austin, Michael T Torchia, Christian M Klare & Robert V Cantu. (2017) Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthopaedica 88:3, pages 351-353.
Read now
Read now
Zeina A. Habib. (2017) Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns. Expert Review of Endocrinology & Metabolism 12:1, pages 59-71.
Read now
Read now
Sunil J. Wimalawansa. (2016) Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. Expert Review of Endocrinology & Metabolism 11:4, pages 329-348.
Read now
Read now
Jörg Schilcher & Per Aspenberg. (2014) Atypical fracture of the femur in a patient using denosumab – a case report. Acta Orthopaedica 85:1, pages 6-7.
Read now
Read now
. (2014) Addendum in print. Acta Orthopaedica 85:1, pages 2-2.
Read now
Read now
Articles from other publishers (39)
Chun Ho Wong, Andy Ka Chun Kan, Kimberly Hang Tsoi, Stacey Sheung Yi Chan, Nancy Su Jiang, Connie Hong Nin Loong, Carol Ho Yi Fong, Janus Siu Him Wong, Graham Ka Hon Shea, Ching Lung Cheung, Chi Ho Lee, Kathryn Choon Beng Tan, Yu Cho Woo & David Tak Wai Lui. (2023) Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis. Endocrine.
Crossref
Crossref
Yao Xiao, Yiqian Chen, Yan Huang & Yuan Xiao. (2023) Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Scientific Reports 13:1.
Crossref
Crossref
A. Strobbe, D. Slock & B. Maeyaert. (2022) Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus. Tijdschrift voor Geneeskunde.
Crossref
Crossref
A. Strobbe, D. Slock & B. Maeyaert. (2022) Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Vincenzo Nasca, Anna Maria Frezza, Carlo Morosi, Ciriaco Buonomenna, Antonina Parafioriti, Giorgio Zappalà, Federica Bini, Paolo Giovanni Casali, Mattia Loppini & Silvia Stacchiotti. (2022) Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. Frontiers in Oncology 12.
Crossref
Crossref
Jeremy Keng Meng Goh, Joyce Suang Bee Koh, Alvin Choong Meng Ng, Meng Ai Png & Tet Sen Howe. (2022) Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report. Calcified Tissue International 111:1, pages 96-101.
Crossref
Crossref
H. E. Skibicki, D. Y. Ponzio, J. A. Brustein, Z. D. Post, A. C. Ong & F. R. Orozco. (2021) A cautionary case: osteoporotic femur fracture after robotic-assisted total knee arthroplasty. Osteoporosis International 32:10, pages 2125-2129.
Crossref
Crossref
Yusuke Fuchioka, Kohji Suzuki, Hiroaki Kimura, Hideto Furuoka & Yuri Tamura. (2021) Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents. Journal of Rural Medicine 16:3, pages 170-173.
Crossref
Crossref
Michael R. McClung. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1737
1755
.
H. I. Piponov, J. M. Goldstein & G. M. Eisenberg. (2020) Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis—a case report. Osteoporosis International 31:11, pages 2263-2267.
Crossref
Crossref
Merav Bar, Susan M. Ott, E. Michael Lewiecki, Kyriakie Sarafoglou, Joy Y. Wu, Matthew J. Thompson, Jonathan J. Vaux, David R. Dean, Kenneth G. Saag, Shahrukh K. Hashmi, Yoshihiro Inamoto, Bhagirathbhai R. Dholaria, Mohamed A. Kharfan-Dabaja, Arnon Nagler, Cesar Rodriguez, Betty K. Hamilton, Nina Shah, Mary E.D. Flowers, Bipin N. Savani & Paul A. Carpenter. (2020) Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation 26:10, pages 1784-1802.
Crossref
Crossref
Denise M van de Laarschot, Malachi J McKenna, Bo Abrahamsen, Bente Langdahl, Martine Cohen-Solal, Núria Guañabens, Richard Eastell, Stuart H Ralston & M Carola Zillikens. (2020) Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. The Journal of Clinical Endocrinology & Metabolism 105:5, pages 1682-1699.
Crossref
Crossref
J. Brett Goodloe, Sarah Toner, Alyssa Althoff, Leah Herzog, Stacey Rothwell & Kristoff Reid. (2020) Bilateral Atypical Femur Fractures Complicated by Carbon Fiber Cephalomedullary Nail Fracture. JBJS Case Connector 10:3, pages e20.00182-e20.00182.
Crossref
Crossref
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi & Toshimi Takano. (2019) Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer 19:1.
Crossref
Crossref
Juan Tan, Hiroshige Sano & Kenneth Poole. (2019) Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. BMJ Case Reports 12:7, pages e229366.
Crossref
Crossref
Tsutomu SugiharaMitsuru KoizumiKeiko HayakawaYoshinori ItoNaohiro Sata. (2018) Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab. Clinical Nuclear Medicine 43:5, pages 365-366.
Crossref
Crossref
Jing Yuan Tan & Cherng Jye Seow. (2017) Management of atypical femoral fracture in a patient with osteogenesis imperfecta. BMJ Case Reports, pages bcr-2017-221835.
Crossref
Crossref
Kenneth Pittman, Yoland C Antill, Amanda Goldrick, Jeffrey Goh & Richard H de Boer. (2017) Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia-Pacific Journal of Clinical Oncology 13:4, pages 266-276.
Crossref
Crossref
David A. Hanley, Michael R. McClung, K. Shawn Davison, Larry Dian, Steve T. Harris, Paul D. Miller, E. Michael Lewiecki & David L. Kendler. (2017) Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. The American Journal of Medicine 130:7, pages 862.e1-862.e7.
Crossref
Crossref
Seiya Ota, Ryo Inoue, Takashi Shiozaki, Yuji Yamamoto, Naoki Hashimoto, On Takeda, Kei Yoshikawa, Junji Ito & Yasuyuki Ishibashi. (2016) Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer 24:4, pages 601-607.
Crossref
Crossref
Samantha Peiling Yang, Tae Won B. Kim, Patrick J. Boland & Azeez Farooki. (2017) Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. The Oncologist 22:4, pages 438-444.
Crossref
Crossref
Ammar Ismail, Amira Hassan Bekhet, Abdelrahman Ibrahim Abushouk, Sahar Mirbaha & Alireza Baratloo. (2017) Denosumab and Atypical Femoral Fractures: A Scoping Literature Review. Trauma Monthly 23:1.
Crossref
Crossref
Nam-Kyong Choi, Daniel H Solomon, Theodore N Tsacogianis, Joan E Landon, Hong Ji Song & Seoyoung C Kim. (2017) Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. Journal of Bone and Mineral Research 32:3, pages 611-617.
Crossref
Crossref
Giuseppe Toro, Cristina Ojeda-Thies, Giampiero Calabrò, Gabriella Toro, Antimo Moretti, Guillermo Martínez-Díaz Guerra, Pedro Caba-Doussoux & Giovanni Iolascon. (2016) Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Olof Sköldenberg, Agata Rysinska, Thomas Eisler, Mats Salemyr, Henrik Bodén & Olle Muren. (2016) Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Edwin Choy, Francis J. Hornicek, Yen-Lin Chen, Daniel I. Rosenthal & Darcy A. Kerr. (2016) Case 26-2016. New England Journal of Medicine 375:8, pages 779-788.
Crossref
Crossref
J. Selga, J. H. Nuñez, J. Minguell, M. Lalanza & M. Garrido. (2015) Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporosis International 27:2, pages 827-832.
Crossref
Crossref
Dam Kim, Yoon-Kyoung Sung, Soo-Kyung Cho, Minkyung Han & Yee-Suk Kim. (2015) Factors associated with atypical femoral fracture. Rheumatology International 36:1, pages 65-71.
Crossref
Crossref
Z. Deniz Olgun, Arianna Gianakos, Jonathan E. Jo & Joseph M. Lane. 2016. Metastatic Bone Disease. Metastatic Bone Disease
121
129
.
Genki Kato, Yasuhiro Shimizu, Yuki Arai, Natsuki Suzuki, Yasutaka Sugamori, Miki Maeda, Mariko Takahashi, Yukihiko Tamura, Noriyuki Wakabayashi, Ramachandran Murali, Takashi Ono, Keiichi Ohya, Setsuko Mise-Omata & Kazuhiro Aoki. (2015) The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Sian Yik Lim, Naina Rastalsky, Edwin Choy & Marcy B. Bolster. (2015) Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone. Bone 81, pages 31-35.
Crossref
Crossref
Sian Yik Lim & Marcy B. Bolster. (2015) Current approaches to osteoporosis treatment. Current Opinion in Rheumatology 27:3, pages 216-224.
Crossref
Crossref
Kareeann Sok Fun Khow & Tuck Yean Yong. (2014) Atypical femoral fracture in a patient treated with denosumab. Journal of Bone and Mineral Metabolism 33:3, pages 355-358.
Crossref
Crossref
K. Lippuner. (2015) Frakturprävention bei der älteren FrauFracture prevention in older women. Gynäkologische Endokrinologie 13:1, pages 33-38.
Crossref
Crossref
Deniz Olgun, Arianna L. Gianakos, Jonathan Jo, Libi Galmer & Joseph M. Lane. 2015. Diagnosis and Management of Hip Disease. Diagnosis and Management of Hip Disease
141
158
.
J.Y. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, P. Emonts & O. Bruyere. (2014) Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice & Research Clinical Endocrinology & Metabolism 28:6, pages 809-834.
Crossref
Crossref
. (2014) Alendronic acid/denosumab. Reactions Weekly 1522:1, pages 19-19.
Crossref
Crossref
Lesley J. Scott. (2014) Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis. Drugs & Aging 31:7, pages 555-576.
Crossref
Crossref
J. Y. Reginster, A. Neuprez, C. Beaudart, M. P. Lecart, N. Sarlet, D. Bernard, S. Disteche & O. Bruyere. (2014) Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs & Aging 31:6, pages 413-424.
Crossref
Crossref